Valuation : Patrys Limited

Market Cap 2.33Cr 1.68Cr 1.45Cr 1.36Cr 1.24Cr 2.33Cr 158.79Cr 16Cr 6.24Cr 81Cr 6.32Cr 6.18Cr 262.46Cr P/E 2024
-4.06x
P/E 2025 -0.68x
Enterprise Value 2.26Cr 1.63Cr 1.4Cr 1.32Cr 1.2Cr 2.25Cr 153.73Cr 16Cr 6.04Cr 79Cr 6.11Cr 5.98Cr 254.1Cr EV / Sales 2024
8.72x
EV / Sales 2025 1.96x
Free-Float
99.37%
Yield 2024 *
-
Yield 2025 -
1 month-9.09%
3 months-30.23%
6 months-21.05%
Current year+7.14%
1 week 0.03
Extreme 0.03
0.03
1 month 0.03
Extreme 0.03
0.04
Current year 0.02
Extreme 0.025
0.05
1 year 0.01
Extreme 0.014999
0.05
3 years 0.01
Extreme 0.011987
0.13
5 years 0.01
Extreme 0.011987
0.56
10 years 0.01
Extreme 0.011987
0.91
Manager TitleAgeSince
Chief Executive Officer - 16/02/2026
Chief Operating Officer - 01/06/2012
Corporate Secretary - 10/11/2025
Director TitleAgeSince
Director/Board Member - 17/06/2025
Chairman 64 -
Director/Board Member - 10/11/2025
Date Insider Type Main position Quantity % Market Cap. Importance
11/08/23 Expiration

Chief Executive Officer

3,96,132 0.0193%
11/08/23 Expiration

Chief Executive Officer

3,283 0.0002%
06/12/21 Buy

Chief Executive Officer

13,37,164 0.0675%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00%+100.01%-75.00% 1.44Cr
-1.79%-3.82%+38.74%+91.90% 6.9TCr
-2.06%-0.18%+41.53%+88.17% 6.63TCr
-0.62%+6.21%-11.67%+377.44% 2.77TCr
+1.08%+1.76%+0.36%-14.86% 2.58TCr
-3.00%-2.61%+34.45%+11.39% 2.65TCr
-1.46%+0.42%+24.07%-18.70% 2.04TCr
-2.96%-16.03%+213.13%+375.00% 1.76TCr
-1.49%-6.69%-4.69%+539.74% 1.51TCr
-0.14%+8.21%+57.62%+164.57% 1.47TCr
Average -1.24%-0.59%+49.35%+153.96% 2.83TCr
Weighted average by Cap. -1.53%-0.45%+39.02%+138.99%

Financials

2024 2025
Net sales 13.94L 10.05L 9L 8L 7L 13.9L 9.49Cr 96.14L 37.31L 4.87Cr 37.74L 36.91L 16Cr 8L 6L 5L 5L 4L 8L 5.64Cr 57.14L 22.17L 2.89Cr 22.43L 21.94L 9.32Cr
Net income -35.39L -25.51L -21.95L -20.65L -18.87L -35.3L -24Cr -2.44Cr -94.71L -12Cr -95.8L -93.71L -40Cr -30.13L -21.72L -18.69L -17.59L -16.06L -30.05L -21Cr -2.08Cr -80.64L -11Cr -81.56L -79.78L -34Cr
Net Debt -22.41L -16.15L -13.9L -13.08L -11.95L -22.35L -15Cr -1.55Cr -59.96L -7.82Cr -60.65L -59.33L -25Cr -7L -5L -5L -4L -4L -7L -5.05Cr -51.2L -19.87L -2.59Cr -20.1L -19.66L -8.35Cr
Logo Patrys Limited
Patrys Limited is an Australia-based company. The Company is focused on the development of its deoxymab platform of cell-penetrating antibodies as therapies for a range of different indications. The Company’s deoxymab platform is based on the deoxymab 3E10 antibody that is identified as an autoantibody in a mouse model of the human disease systemic lupus erythematosus (SLE). It has developed two humanized forms of deoxymab 3E10, called PAT-DX1 and PAT-DX3, which have improved activity over the original 3E10 antibody. PAT-DX1 is a dimer of a small antibody fragment derived from a humanized version of the binding domain from the original mouse deoxymab antibody 3E10. PAT-DX3 is a humanized, full-sized antibody that has been further optimized to improve its therapeutic potential. It is also focused on developing RLS-2201, a proprietary injectable formulation of quetiapine.
Employees
10
Date Price Change Volume
04/26/04 A$0.0300 0.00% 6,20,799
03/26/03 A$0.0300 0.00% 9,69,792
02/26/02 A$0.0300 -3.23% 5,82,118
01/26/01 A$0.0310 +3.33% 17,733
31/26/31 A$0.0300 -3.23% 1,02,429